David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Elad Levy will present results of the clinical trial that assessed the safety of Synchron’s endovascular brain-computer ...

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study ...

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to ...

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of ...